Shuttle Pharmaceuticals Holdings, Inc.
News
(3)April 2026
SHPH Files Amendment to Report; Content Needed for Analysis
# ❓ What This Document Is This document was intended to be an SEC filing for Shuttle Pharmaceuticals Holdings, Inc., specifically an ARS (Amendment to Report). An ARS is typically used when the company needs to formally correct or update information that was presented in a previous filing. Essential
SHPH seeks authorization for wide-range reverse stock split proposal
# 📄 What This Document Is 📜 This is a Definitive Proxy Statement (Form DEF 14A) for Shuttle Pharmaceuticals Holdings, Inc. It's essentially a detailed packet of documents that comes to shareholders before an Annual Meeting. Its primary purpose is to educate shareholders on who the company is, who
SHPH Seeks Reverse Stock Split to Maintain Nasdaq Listing
# 📄 What This Document Is This is a **PRE 14A**, a *preliminary proxy statement*. It's a formal document sent to shareholders ahead of a company's annual meeting. Its job is to explain what will be voted on and provide the information shareholders need to make informed decisions. 👉 **Why it matte
Peers in Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited